服用离子通道阻滞剂患者发生多形性胶质母细胞瘤的风险。
Risk of Glioblastoma Multiforme in Patients Taking Ion Channel Blockers.
作者信息
Hallan David R, Tankam Cyril S, Harbaugh Thaddeus, Rizk Elias
机构信息
Neurosurgery, Penn State Health Milton S. Hershey Medical Center, Hershey, USA.
出版信息
Cureus. 2022 Oct 13;14(10):e30277. doi: 10.7759/cureus.30277. eCollection 2022 Oct.
Background Ion channels play a role in the development and progression of glioblastoma multiforme. This study investigates the association between the risk of developing glioblastoma multiforme in patients taking these medications. Methods A retrospective propensity score-matched analysis was performed using the TriNetX multinational electronic health record database for patients taking verapamil, digoxin, amiodarone, or diltiazem versus those not taking these medications. The outcome of interest was the incidence of glioblastoma multiforme. Results Verapamil users had an OR of 0.494 (p < 0.0001) of developing glioblastoma versus verapamil non-users. Patients on digoxin had an OR of 0.793 (p = 0.2393), patients on amiodarone had an OR of 0.600 (p = 0.0035), patients on diltiazem had an OR of 0.584 (p < 0.0001), and patients on verapamil, digoxin, amiodarone, or diltiazem had an OR of 0.641 (p < 0.0001) of developing glioblastoma versus patients not taking these medications. Conclusion In patients taking the ion channel blockers diltiazem, amiodarone, or verapamil, the odds of developing glioblastoma multiforme were lower than in patients not taking these medications.
背景
离子通道在多形性胶质母细胞瘤的发生和发展中起作用。本研究调查服用这些药物的患者发生多形性胶质母细胞瘤风险之间的关联。方法：使用TriNetX跨国电子健康记录数据库，对服用维拉帕米、地高辛、胺碘酮或地尔硫䓬的患者与未服用这些药物的患者进行回顾性倾向评分匹配分析。感兴趣的结果是多形性胶质母细胞瘤的发病率。结果：与未服用维拉帕米的患者相比，服用维拉帕米的患者发生胶质母细胞瘤的比值比为0.494（p<0.0001）。服用地高辛的患者比值比为0.793（p = 0.2393），服用胺碘酮的患者比值比为0.600（p = 0.0035），服用地尔硫䓬的患者比值比为0.584（p<0.0001），与未服用这些药物的患者相比，服用维拉帕米、地高辛、胺碘酮或地尔硫䓬的患者发生胶质母细胞瘤的比值比为0.641（p<0.0001）。结论：在服用离子通道阻滞剂地尔硫䓬、胺碘酮或维拉帕米的患者中，发生多形性胶质母细胞瘤的几率低于未服用这些药物的患者。
Zotero 插件